
|Articles|November 2, 2012
Similar bleeding rates seen with two anticoagulants
Bleeding rates associated with new use of dabigatran (Pradaxa, Boehringer Ingelheim) do not appear to be higher than bleeding rates associated with new use of warfarin, according to an FDA safety review of post-market reports of serious bleeding events.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Eli Lilly, Walmart Announce Expansion of Direct-to Consumer Access for Tirzepatide
2
White House Announces Action to Increase Competition, Decrease Cost of Biosimilar Development
3
FDA Approves Mirikizumab as Once Monthly Injection for Moderately to Severely Active Ulcerative Colitis
4
American Pharmacists Month: Clinical Service Expansion Benefits Patient Outcomes, Pharmacist Profession
5


























































































































































